Xtandi 40 MG capsule 120S
Ended Awarded
- Contract number
- SPE2DB26FNMNV
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,509
Award facts
- Contract value 100% obligated
- $12,508.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,508.77 to DMS Pharmaceutical Group Inc. for XTANDI 40 mg capsules (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR. This underlying IDC, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors within the broader $30.3 billion PPV-G GEN V acquisition strategy.
The PPV-G GEN V program authorizes the Defense Logistics Agency to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support the recurring medical supply needs of Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group's product portfolio encompasses oncology treatments, immunosuppressants, specialty pharmaceuticals, vaccines, and routine medications, demonstrating substantial capability to fulfill the diverse pharmaceutical requirements of the federal military medical system. The contract structure enables the company to serve as a critical supplier for DoD healthcare operations globally, with performance on numerous prior delivery orders validating its ability to meet specialized federal pharmaceutical demands.
Quick answers
Who was awarded contract SPE2DB26FNMNV?
SPE2DB26FNMNV was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DB26FNMNV worth?
The government has obligated $12,509 on SPE2DB26FNMNV.
Is contract SPE2DB26FNMNV an order under another contract?
Yes. SPE2DB26FNMNV is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNV competed?
The extent of competition for SPE2DB26FNMNV was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award